Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2011 Financial Results

Earnings release after close of market, May 3, 2011

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2011 financial results after the Nasdaq market closes on Tuesday, May 3, 2011.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday morning, May 4, 2011 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Participants can access the live conference call by dialing 800-894-5910, (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 800-753-5212 (US) or 402-220-2673 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.